Top

Strahlentherapie und Onkologie

Published in:

01-03-2015 | Literatur kommentiert

Langzeitergebnisse von Patienten mit muskelinvasiven Harnblasenkarzinomen nach multimodaler, organerhaltender Therapie

Analyse der RTOG-Studienprotokolle

Author: PD Dr. Christian Weiss

Published in: Strahlentherapie und Onkologie | Issue 3/2015

Auszug

Mehrere prospektive Studien der Radiation Therapy Oncology Group (RTOG) untersuchten blasenerhaltende multimodale Therapiestrategien (CMT) für Patienten mit muskelinvasiven Harnblasenkarzinomen (MIBC). Die radikale Zystektomie war dabei reserviert für Patienten mit Rest- oder Rezidivtumoren. Nun wurden die Langzeitergebnisse aller in den verschieden Studien eingeschlossenen Patienten analysiert. …

Rodel C, Weiss C, Sauer R (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536–5544CrossRefPubMed

Mak RH, Hunt D, Shipley WU et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32:3801–3809

Hautmann RE, de Petriconi RC, Pfeiffer C et al (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61:1039–1047CrossRefPubMed

Dalbagni G, Genega E, Hashibe M et al (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165:1111–1116CrossRefPubMed

Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675PubMed

Efstathiou JA, Spiegel DY, Shipley WU et al (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705–711CrossRefPubMed

Shipley WU, Kaufman DS, Zehr E et al (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60:62–67 (discussion 67–68)CrossRefPubMed

Krause FS, Walter B, Ott OJ et al (2011) 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 31:985–990PubMed

Rodel C, Grabenbauer GG, Kuhn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071CrossRefPubMed

10.

Dunst J, Sauer R, Schrott KM et al (1994) Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 30:261–266CrossRefPubMed

11.

Hoskin PJ, Rojas AM, Bentzen SM et al (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912–4918CrossRefPubMed

12.

James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477–1488CrossRefPubMed

13.

Weiss C, Wittlinger M, Engehausen DG et al (2008) Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 70:1502–1506CrossRefPubMed

14.

Zietman AL, Grocela J, Zehr E et al (2001) Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58:380–385CrossRefPubMed

15.

Gray PJ, Fedewa SA, Shipley WU et al (2013) Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base. Eur Urol 63:823–829CrossRefPubMed

Title: Langzeitergebnisse von Patienten mit muskelinvasiven Harnblasenkarzinomen nach multimodaler, organerhaltender Therapie
Analyse der RTOG-Studienprotokolle
Author: PD Dr. Christian Weiss
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 3/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0814-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Langzeitergebnisse von Patienten mit muskelinvasiven Harnblasenkarzinomen nach multimodaler, organerhaltender Therapie

Analyse der RTOG-Studienprotokolle

Auszug

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 3/2015

Ist eine axilläre Lymphknotendissektion bei N1-Situation nach Sentinel-Lymphknoten-Biopsie und Mastektomie wegen Mammakarzinom nötig?

Präoperative Kurzzeitradiotherapie kombiniert mit volldosierter Langzeitchemotherapie beim lokal fortgeschrittenen Rektumkarzinom

Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer

Commentary on “Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme”

Response to commentary by Champ and Klement

Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy